The first vector-delivered gene therapies to receive FDA approval for clinical use were Luxturna,1 Spark Therapeutics’ vision loss cure, and Zolgensma,2 Novartis’ spinal muscular atrophy treatment.

Austin, United States, June 09, 2026 (GLOBE NEWSWIRE) -- "The Viral Vector Production (Research-use) Market was valued at USD 1.95 billion in 2025 and is projected to reach USD 8.26 billion by 2035, ...

Efficient viral vector production is essential for the cost-effective manufacture of cell and gene therapies. Many of the current production workflows are reliant on basal media in batch-mode, which ...

Viral vectors are vital for the cell and gene therapy industry. However, long production timelines, combined with quality and consistency issues, mean that growing demand is outstripping supply. The ...

CDMO ProBio, the biologics subsidiary of GenScript, expanded its plasmid DNA and viral vector production capacity with the opening of new manufacturing facility in Hopewell, New Jersey. The site, ...

Viral vector service expansion empowers scientists by offering high-quality research reagents through on-demand AAV production from Addgene’s vast plasmid repository WATERTOWN, Mass.--(BUSINESS WIRE)- ...

Ajinomoto CELLiST Korea, a subsidiary of the Ajinomoto Group specializing in the development and manufacturing of cell culture media, has launched CELLiSTTM AAV Production Supplement 1, a newly ...

Lentiviral vectors are derived from lentiviruses such as HIV-1 and serve as potent gene delivery vehicles due to their capacity to integrate stably into the host genome and transduce both dividing and ...

WALTHAM, Mass.--(BUSINESS WIRE)--ElevateBio, LLC (ElevateBio), a technology-driven company focused on powering transformative cell and gene therapies, today announced four poster presentations at the ...